– Serve You Rx, a full-service pharmacy benefit manager (PBM), is expanding its cost-saving solutions by incorporating Otulfi™ and Yesintek™, biosimilars to the widely used specialty drug Stelara®.

“The numbers tell the story here,” stated Justin Jasniewski, CEO of Serve You Rx. “With savings of up to 96% compared to as much as $152,000 annually for Stelara, these biosimilars represent a significant opportunity for our clients to manage healthcare costs while maintaining quality care for their members.”

This initiative is a collaborative effort with Mark Cuban Cost Plus Drugs and Waltz Health, aimed at improving access to high-cost specialty medications through transparent pricing and simplified distribution channels.

“Making biosimilars like Otulfi available through Cost Plus Drugs is another step toward breaking down barriers to access,” said Dr. Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. “By working with Serve You Rx, we’re helping more patients and health plans avoid the inflated costs that have defined the specialty drug market for too long.”

Details of the distribution include:

Both medications will be supported by robust copay assistance programs to ensure patient access without imposing financial barriers.

Waltz Health offers a comprehensive solution that includes a specialty pharmacy network competing on price and service, a guided patient experience, and a flexible service model designed to balance cost and patient outcomes.